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Abstract: Two decades since the discovery of the RNA interference (RNAi) pathway, we are now 
witnessing the approval of the first RNAi-based treatments with small interfering RNA (siRNA) 
drugs. Nevertheless, the widespread use of siRNA is limited by various extra- and intracellular 
barriers, requiring its encapsulation in a suitable (nanosized) delivery system. On the intracellular 
level, the endosomal membrane is a major barrier following endocytosis of siRNA-loaded 
nanoparticles in target cells and innovative materials to promote cytosolic siRNA delivery are 
highly sought after. We previously identified the endogenous lung surfactant protein B (SP-B) as 
siRNA delivery enhancer when reconstituted in (proteo) lipid-coated nanogels. It is known that the 
surface-active function of SP-B in the lung is influenced by the lipid composition of the lung 
surfactant. Here, we investigated the role of the lipid component on the siRNA delivery-promoting 
activity of SP-B proteolipid-coated nanogels in more detail. Our results clearly indicate that SP-B 
prefers fluid membranes with cholesterol not exceeding physiological levels. In addition, SP-B 
retains its activity in the presence of different classes of anionic lipids. In contrast, comparable 
fractions of SP-B did not promote the siRNA delivery potential of DOTAP:DOPE cationic liposomes. 
Finally, we demonstrate that the beneficial effect of lung surfactant on siRNA delivery is not limited 
to lung-related cell types, providing broader therapeutic opportunities in other tissues as well. 
Keywords: siRNA delivery; nanoparticles; pulmonary surfactant 
 
1. Introduction 
Over the last two decades, research in the field of RNAi therapeutics has gained attention as it 
allows to address diseases at the transcriptome level [1]. Once they reached the cytosol, small 
interfering RNAs (siRNAs) activate the RNAi machinery, leading to post-transcriptional gene 
silencing through sequence-specific degradation of mRNA [2,3]. High target specificity and 
versatility of this emerging class of therapeutics represent some of the main advantages compared to 
conventional small molecule drugs and monoclonal antibodies, providing a wide range of biomedical 
uses [1,3]. However, their application in the clinic is limited by many extra- and intracellular delivery 
barriers. Most importantly, negatively charged hydrophilic macromolecules like siRNAs cannot cross 
biological membranes, making cellular delivery challenging [1,4]. 
Viral vectors are often applied carriers to guide cellular delivery of nucleic acids. However, 
labor-intensive large-scale production and safety issues remain important drawbacks, hence 
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encouraging research for non-viral alternatives [4–6]. Encapsulation of siRNA into synthetic 
nanoparticles (NPs) allows its internalization by cells through endocytosis followed by release of the 
encapsulated RNA into the cytosol (i.e., endosomal escape). Among the vast number of NPs under 
investigation, cationic lipid nanoparticles (LNPs) currently are the preferred material for RNA 
delivery [7]. To date, many cationic lipid materials have been synthetized for LNP production [8–13]. 
However, the endosomal escape efficiency often remains poor [4,14–16]. Moreover, concerns remain 
regarding their safety and immunogenicity [12,17]. As such, to expedite clinical translation of this 
highly promising class of therapeutics, lipid-based siRNA formulations are needed to merge efficient 
cellular delivery with acceptable toxicity. 
As synthetic polymer-and lipid-based NPs often fail to combine biocompatibility and efficacy, 
there is a growing interest in using bio-inspired materials [18]. We recently reported on a bio-inspired 
nanocomposite, composed of a siRNA-loaded polymeric matrix core surrounded by a shell of clinical 
pulmonary surfactant, i.e., poractant α (Curosurf®) (Figure 1) [19]. 
 
Figure 1. Visual representation of the core-shell surfactant-coated nanogel structure. SiRNA-loaded 
dextran nanogels (siNGs) were coated with Curosurf® (poractant α; porcine derived clinical 
pulmonary surfactant (PS)) or with a PS-inspired lipid coating containing the surfactant protein B (SP-
B) and an anionic lipid mixture. PC = phosphatidylcholine, PG = phosphatidylglycerol. 
Pulmonary surfactant (PS) is a surface-active material that is produced and secreted into the 
alveolar space by specialized alveolar type II epithelial cells. PS covers the entire alveolar surface and 
its main physiological role is to maintain low surface tension upon expiration to prevent alveolar 
collapse [20]. Natural human PS has a complex composition of lipids (~90 wt%) and proteins (~10 
wt%). The lipid fraction mainly contains zwitterionic phosphatidylcholine (PC) (~60–70 wt%) as well 
as anionic phosphatidylglycerol (PG) (~10 wt%) species and neutral lipids, of which cholesterol is the 
most abundant (~8–10 wt%). The protein fraction consists of two major classes of specialized 
surfactant proteins (SPs), i.e., the larger and hydrophilic SP-A and SP-D, as well as the smaller 
hydrophobic SP-B and SP-C [21,22]. PS has been extensively studied mainly because of its functional 
role in mammalian breathing [22,23]. In the context of inhalation therapy with nanomedicines, PS is 
primarily regarded as one of the extracellular barriers in the deep lung that needs to be overcome to 
gain access to underlying target cells upon inhalation therapy [21]. Its current therapeutic use is 
limited to the treatment of respiratory distress syndrome in premature infants, where modified PS 
from animal origin (e.g., Curosurf®) is approved for so-called surfactant replacement therapy [23]. 
Unexpectedly, we observed that the PS outer layer in the above mentioned nanocomposites 
significantly enhanced intracellular siRNA delivery in lung epithelial cells and (primary) alveolar 
macrophages [21,24]. Although it constitutes only a minor fraction in PS, surfactant protein B (SP-B) 
was identified as a key component for the improved RNA delivery (Figure 1) [25]. The beneficial 
effect of PS and the PS-associated SP-B on RNA delivery is a very recent finding and therefore 
remains largely unexplored in the literature. Qiu and colleagues reported on the cationic amphiphilic 
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peptide KL4, a synthetic SP-B mimic, as siRNA carrier for lung delivery, reaching efficient delivery 
in vitro [26]. The Anderson group covalently conjugated the truncated cationic domain of SP-B to the 
surface of lipidoid NPs to improve siRNA delivery [27]. 
Hence, many questions remain on this unique function of PS and native SP-B. First, given its 
natural origin, proof-of-concept on SP-B promoted siRNA delivery has been limited to lung-related 
cell types. Here, we sought to confirm this specific activity of SP-B on other cell types as well. In 
addition, our earlier data suggest that the type of lipid with which the SP-B is associated, can 
influence its siRNA delivery efficiency. In this report, we therefore investigated the importance of the 
lipid composition on the siRNA delivery activity of SP-B in more detail. In particular, the impact of 
cholesterol, membrane fluidity and anionic lipid type in the SP-B inspired proteolipid shell of the 
nanocomposites is probed. Finally, we sought to reconstitute the cationic amphiphilic SP-B in 
DOTAP:DOPE cationic liposomes with the aim to promote their cellular siRNA delivery efficiency. 
2. Materials and Methods 
2.1. Small Interfering RNAs 
Twenty-one nucleotide small interfering RNA (siRNA) duplexes targeting Enhanced Green 
Fluorescent Protein (siEGFP), non-targeting negative control duplexes (siCTRL), protein tyrosine 
phosphatase receptor type C (siCD45) and pGL3 firefly luciferase (siLuc) were purchased from 
Eurogentec (Seraing, Belgium). For cellular uptake experiments, the siCTRL duplex was labeled with 
a Cy5® dye at the 5′ end of the sense strand (siCy5). The fluorescent labeling was performed and 
verified by Eurogentec. The concentration of the siRNA stock solutions in nuclease-free water 
(Ambion®-Life Technologies, Ghent, Belgium) was calculated from absorption measurements at 260 
nm (1 OD260 = 40 μg/mL) with a NanoDrop 2000c UV-Vis spectrophotometer (Waltham, MA, USA). 
For siEGFP: sense strand = 5′-CAAGCUGACCCUGAAGUUCtt-3′; antisense strand = 5′-
GAACUUCAGGGUCAGCUUGtt-3′. For siCTRL: sense strand = 5′-
UGCGCUACGAUCGACGAUGtt-3′; antisense strand = 5′-CAUCGUCGAUCGUAGCGCAtt-3′. For 
siCD45: sense strand = 5′-GAA-GAA-UGC- UCA-CAG-AUA-A-3′; antisense strand = 5′-UUA-UCU-
GUG-AGC-AUU-CUU-C-3′ (capital letters represent ribonucleotides; lower case letters represent 2′-
deoxyribonucleotides). The sequence of siLuc is confidential and not available to be listed. 
2.2. Synthesis of Dextran Nanogels and siRNA Complexation 
Dextran hydroxyethyl methacrylate (dex-HEMA) or dextran methacrylate (dex-MA) [18,28–30] 
was copolymerized with a cationic methacrylate monomer [2-(methacryloyloxy)ethyl]- trimethyl-
ammonium chloride (TMAEMA) to produce cationic dex-HEMA-co-TMAEMA (degree of 
substitution (DS) of 5.2) and dex-MA-co-TMAEMA (DS of 5.9) nanogels (hereafter abbreviated as 
respectively dex-HEMA NGs and dex-MA NGs), using an inverse miniemulsion 
photopolymerization method as previously reported [24,25,31–33]. The synthetized NGs were 
lyophilized and stored desiccated to ensure long term stability. To make siRNA-loaded nanogels 
(siNGs), 2 mg/mL of NG stock solutions were prepared by dispersing a weighed amount of the 
lyophilized nanoparticles in ice-cooled nuclease-free water, followed by brief sonication (Branson 
Ultrasonics Digital Sonifier®, Danbury, CT, USA). To allow siRNA complexation, equal volumes of 
siRNA and NGs in (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) buffer (20 mM, pH 
7.4) were mixed and incubated for ≥ 10 min at 4 °C. 
2.3. Preparation of Proteolipid-Coated Nanogels 
The commercially available clinical lung surfactant derived from minced porcine lungs, 
Poractant α (Curosurf®) (Chiesi Pharmaceuticals, Parma, Italy), was used to form the pulmonary 
surfactant (PS) outer layer on siNGs. To prepare the PS-inspired proteolipid coating the following 
lipids were used: 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3- 
phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), L-α-phosphatidyl- 
glycerol from egg yolk (egg PG), L-α-phosphatidyl-L-serine (soy PS) and L-α-phosphatidylinositol 
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from soy (soy PI). Soy PS was purchased from Sigma-Aldrich, all other lipids were obtained from 
Avanti Polar Lipids (Alabaster, AL, USA). SP-B was isolated from native porcine pulmonary 
surfactant following a procedure described earlier by Pérez-Gil and coworkers [34]. The lipids with 
or without SP-B (0.4 wt%) were mixed at the required weight ratios in chloroform and a (proteo) lipid 
film was obtained via nitrogen flow or rotary evaporation. The resulting lipid film was hydrated 
using HEPES buffer (20 mM, pH 7.4) and subsequently mixed with equal volumes of the previously 
formed siNGs (15 mg lipid/mg nanogel) [25]. The formation of the proteolipid coat was obtained by 
≥ 10 min incubation at 4 °C and three 10″ cycles of high-energy sonication (amplitude 10%), using a 
probe sonicator (Branson Ultrasonics Digital Sonifier®, Danbury, CT, USA). To obtain Curosurf-
coated siNGs (CS-NGs), the Curosurf® dispersion (80 mg/mL) was diluted in HEPES buffer and 
mixed in equal volumes with the previously formed siNGs (15 mg lipid/mg nanogel), following an 
identical incubation and sonication protocol as detailed above. Hydrodynamic diameter, dispersity 
(Ð) and ζ-potential of all formulations were measured via Dynamic Light Scattering (DLS) (Zetasizer 
Nano, Malvern Instruments, Worcestershire, UK). 
2.4. Preparation of Cationic Liposomes 
To prepare cationic liposomes, 1,2-dipalmitoyl-3-trimethylammonium-propane (DOTAP) and 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were purchased from Avanti Polar Lipids 
(AL, USA). DOTAP:DOPE liposomes (50:50 molar ratio) were prepared by mixing appropriate 
amount of the mentioned lipids in chloroform in a round bottom flask. In the case of 
DOTAP:DOPE:SP-B liposomes, 1 wt% of SP-B was added to the lipid mixture in chloroform. A lipid 
film was obtained via rotary evaporation and subsequently hydrated with HEPES buffer (20 mM, pH 
7.4). The lipid or lipid-protein dispersion was sonicated using a probe sonicator (Branson Ultrasonics 
Digital Sonifier®, Danbury, CT, USA) for 30″ via a pulsed program using 10% amplitude. 
DOTAP:DOPE liposomes were complexed with siRNA at a charge ratio (nitrogen/phosphate ratio) 
equal to 8, to obtain the formation of the so-called lipoplexes (LPX). Hydrodynamic diameter, 
dispersity (Ð) and ζ-potential of all formulations were measured via Dynamic Light Scattering (DLS) 
(Zetasizer Nano, Malvern Instruments, Worcestershire, UK). 
2.5. Cell Lines and Culture Conditions 
Cell culture experiments were performed using a human non-small cell lung cancer cell line 
stably expressing EGFP (H1299_eGFP) [25], a human ovarian cancer cell line stably expressing 
luciferase (SKOV3_LUC) [35], a human hepatoma cell line stably expressing eGFP (Huh-7_eGFP) [36] 
and a murine alveolar macrophage cell line (MH-S). The H1299_eGFP and SKOV-3_LUC were 
respectively obtained from the lab of Prof. Foged (Department of Pharmacy, University of 
Copenhagen, Copenhagen, Denmark) and the lab of Prof. Aigner (Institute of Pharmacology, 
Pharmacy and Toxicology, University of Leipzig, Leipzig, Germany). The Huh-7 cell line was 
obtained from the lab of Prof. Lahoutte, (VUB, Brussels, Belgium). Huh-7_eGFP were generated by 
transfecting Huh-7 cells with the pEGFP-N2 plasmid (Clontech, Palo Alto, CA, USA). The MH-S cell 
line was provided by VIB-UGent. H1299_eGFP cells were cultured in RPMI 1640, supplemented with 
10% fetal bovine serum, 2 mM glutamine and 100 U/mL penicillin/streptomycin. Cells were treated 
with medium containing 1 mg/mL Geneticin® once per month. SKOV-3_LUC were cultured in 
McCoy’s 5A medium, supplemented with 10% FBS and 100 U/mL penicillin/streptomycin. Huh-
7_eGFP cells were cultured in DMEM:F12 supplemented with 10% fetal bovine serum, 2 mM 
glutamine and 100 U/mL penicillin/streptomycin. MH-S were cultured in RPMI 1640 supplemented 
with 2 mM glutamine, 10% fetal bovine serum, 100 U/mL penicillin/streptomycin, 10 mM HEPES, 1 
mM sodium pyruvate and 0.05 mM 2-mercaptoethanol. All cells were cultured at 37 °C in a 
humidified atmosphere containing 5% CO2 and were passed every 3 days using a 0.25% trypsin-
ethylenediaminetetraacetic acid (EDTA) solution to maintain subconfluency. All cell culture 
materials were purchased from Gibco®-Life Technologies, except for the serum, which was delivered 
by Hyclone™ (Thermo Fisher Scientific, Waltham, MA, USA). 
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2.6. Quantification of In Vitro Cellular siRNA Uptake by Flow Cytometry 
To quantify the cellular internalization of siRNA via flow cytometry, H1299_eGFP cells (2 × 104 
cells/cm2 in 24-well plates), MH-S cells (4 × 104 cells/cm2 in 12-well plates), Huh-7_eGFP cells (4 × 104 
cells/cm2 in 24-well plates) or SKOV-3_LUC cells (1.85 × 104 cells/cm2 in 24-well plates) were plated 
(Greiner Bio-One GmbH, Kremsmünster, Austria) and allowed to settle overnight. NGs were loaded 
with siCTRL:siCy5 (100:0.75 mol%) and coated with a proteolipid mixture using the procedure 
described above. The particles were diluted 5 times in Opti-MEM to a final concentration of 30 µg/mL 
and incubated with the cells for 4 h (37 °C, 5% CO2). Next, the cells were washed with dextran sulfate 
sodium salt (0.1 mg/mL in PBS) to remove cell surface-bound fluorescence prior to flow cytometric 
quantification. To quantify uptake percentage, the mean fluorescence intensity (MFI) of cells treated 
with coated NGs were normalized to the ones of cells treated with uncoated NGs (representing 
100%). For cationic liposomes, H1299_eGFP cells were seeded in 96-well plates (SPL Lifesciences Co. 
Ltd., Gyeonggi-do, South Korea) at a density of 2 × 104 cells/cm2 and allowed to settle overnight. 
Liposomes were used for complexation of a mixture of siCTRL:siCy5 (90:10 mol%), diluted in Opti-
MEM, and incubated with the cells for 4 h (37 °C, 5% CO2), followed by flow cytometric analysis as 
mentioned above. Data analysis was performed using the FlowJoTM analysis software (Treestar, Costa 
Mesa, CA, USA). 
2.7. Quantification of eGFP Gene Silencing by Flow Cytometry 
To quantify gene knockdown efficiency, H1299_eGFP cells (2 × 104 cells/cm2) or Huh-7_eGFP (4 
× 104 cells/cm2) were plated in 24-well plates (Greiner Bio-One GMBH) and allowed to settle 
overnight. Particles were prepared in Opti-MEM as described above and incubated with the cells (4 
h at 37 °C and 5% CO2). Next, cells were washed with PBS and incubated with 1 mL fresh cell culture 
medium for 48 h. At this point, cells were prepared for flow cytometry as described above and a 
minimum of 104 cells were analyzed for each sample. The eGFP expression percentage was calculated 
normalizing the MFI of cells treated with siEGFP to the MFI of cells treated with siCTRL. Data 
analysis was performed using the FlowJoTM analysis software (Version 10.5.3, Treestar, Costa Mesa, 
USA, 1997-2018). 
2.8. Luciferase Silencing in Human Ovarian Carcinoma Cells 
SKOV-3_LUC were seeded in 24-well plates at a density of 1.85 × 104 cells/cm2 and allowed to 
attach overnight. Particles were prepared as described above and diluted in Opti-MEM before 
incubation with the cells (4 h at 37 °C and 5% CO2). Next, cells were washed with PBS and incubated 
with 1 mL fresh cell culture medium for 24 h. At this time point, cell culture medium was removed 
and the cells were washed with PBS. Subsequently, luminescence was measured using the Luciferase 
Reporter Assay Kit, following the optimized Promega protocols and reagents. Luciferase activity of 
each sample was assayed in a GloMax™ 96 Luminometer (Promega, Madison, WI, USA). 
2.9. Quantification of In Vitro CD45 Silencing in MH-S by Flow Cytometry 
MH-S cells were seeded in 12-well plates and allowed to settle overnight. Particles were 
prepared as described above and diluted in Opti-MEM (final NG concentration of 30 µg/mL; final 
siRNA concentration of 100 nM) before incubation with the cells (4 h at 37 °C and 5% CO2). 
Afterwards, the cells were washed with PBS and 1 mL of culture medium was added. Forty-eight 
hours after transfection, the cells were detached with a non-enzymatic cell dissociation buffer (10 min 
incubation at 37 °C). After centrifugation (7 min, 300 g), the cell pellet was resuspended in staining 
buffer (PBS supplemented with 5% FBS). High-affinity Fc receptors were blocked by incubation with 
purified anti-mouse CD16/CD32 (BD Biosciences, Erembodegem, Belgium) for 15 min at 4 °C. 
Subsequently, the cells were incubated with PerCP-Cy® 5.5 rat anti-mouse CD45 (BD Biosciences) 
diluted in staining buffer and put on a rotary shaker for 45 min at room temperature for incubation. 
Following three washing steps with 1 mL staining buffer, the cell pellet was resuspended in 500 μL 
flow buffer and placed on ice until flow cytometry analysis. Subsequently cells were analyzed using 
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a FACSCaliburTM flow cytometer (BD Biosciences, Erembodegem, Belgium). The fluorescence for the 
Cy® 5.5-label was measured at 488/690 nm. Data analysis was performed using the FlowJo™ analysis 
software (Treestar, Costa Mesa, USA). 
2.10. Statistical Analysis 
All experiments were performed in technical triplicate and with ≥ 2 independent biological 
repeats (≥ n = 2), unless otherwise stated. All data are presented as mean ± standard deviation (SD). 
Statistical analysis was performed via one way ANOVA, unless otherwise stated, followed by a 
Bonferroni multiple comparison test, using GraphPad Prism software version 8. 
3. Results and Discussion 
3.1. Pulmonary Surfactant (PS) Potentiates siRNA Delivery in Non-Pulmonary Cell Lines 
As mentioned above, earlier work has demonstrated improved siRNA delivery and targeted 
gene silencing with PS-coated nanocomposites in both non-small cell lung cancer cells (H1299) and 
alveolar macrophages [21,24,25]. Corroborating these results, as shown in Figure 2a, layering cationic 
siNGs with a negatively charged PS bilayer (i.e., Curosurf®) strongly reduces cellular uptake in the 
H1299 cell line. Importantly, despite the lower intracellular siRNA dose, the same level of targeted 
gene knockdown is obtained (Figure 2b), indicating that the CS coat enhances the fraction of the 
internalized siRNA dose that is delivered into the cytosol. A comparable outcome was obtained for 
the murine alveolar macrophage cell line MH-S, targeting the CD45 gene (Figure 2c,d). To evaluate 
if PS can likewise promote siRNA delivery in cell lines derived from other organs, human ovarian 
carcinoma cells (SKOV-3) and human hepatoma cells (Huh-7) were treated with CS-coated siNGs 
(Figure 2e–h). Consistent with earlier reports, the anionic CS outer layer significantly inhibited 
cellular internalization of siNGs in both cell types. However, despite the ≥4-fold reduction in 
intracellular siRNA dose, also in these cell lines a comparable knockdown of the targeted reporter 
genes relative to the uncoated siNGs was observed, albeit that the Huh-7 reporter cell line in general 
appeared to be more difficult to transfect. These data support the notion that although the lungs 
constitute the natural habitat of lung surfactant, its beneficial effect on intracellular siRNA delivery 
is not limited to lung-related cell types and that PS-inspired drug delivery should not be restricted to 
the lungs as main target tissue. 
Pharmaceutics 2019, 11, x 7 of 17 
 
 
Figure 2. Biological efficacy of surfactant-coated nanogels on (non-)pulmonary cell lines. (a, c, e, g) 
Flow cytometric quantification of cellular uptake of siCy5-loaded nanogels (siNGs) with and without 
Curosurf® (CS) coating. (b, d, f, h) Gene silencing potential of siNGs and Curosurf®- coated NGs 
(siNGs-CS). Despite the strongly reduced cellular uptake of siNGs following Curosurf® coating, both 
formulations reach comparable levels of gene knockdown on the different cell lines studied. 
Experiments were performed with a fixed NG concentration (30 µg/mL) and siRNA concentration (50 
nM), except for the MH-S cell line, for which we used a final siRNA concentration of 100 nM. 
Experiments on H1299_eGFP and silencing of MH-S cell lines are the result of three independent 
biological repeats (n = 3), other experiments are performed in technical triplicate. 
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3.2. The Activity of SP-B Is Dependent on Its Lipid Microenvironment 
In recent work, Merckx et al. revealed that surfactant protein B (SP-B) is a key component in lung 
surfactant that dictates cellular siRNA delivery [25]. However, the activity of SP-B was proven to be 
strongly dependent on the type of lipids with which it is combined, with the more fluid lipid mixture 
DOPC:PG (85:15 wt%) clearly outperforming its more rigid counterpart DPPC:PG (85:15 wt%) in 
terms of in vitro siRNA delivery efficiency. It is postulated that less resistance against lateral 
movement in a less rigid proteolipid coat could promote SP-B-mediated intermembrane interactions 
[34,37]. To extend our understanding, siNGs were coated with DSPC:PG (85:15 wt%) of which the 
main lipid has a substantially higher phase transition temperature (Tc) of 55 °C, compared to DPPC 
(41 °C). The absence of SP-B in the lipid coat inhibited siNG-mediated gene silencing, independent 
of the type of lipid used. Supplementation of the DOPC:PG and DPPC:PG lipid coat with SP-B did 
result in reduced eGFP expression levels, albeit that the improvement in gene silencing was 
statistically significant solely for the more fluid DOPC-containing lipid bilayer (Figure 3a). 
Importantly, with DSPC as main phospholipid, no gene silencing could be observed anymore. Of 
note, using an identical coating protocol, the use of DSPC as main lipid component resulted in 
micrometer sized nanocomposites (Table 1). These data altogether suggest that the Tc of the lipid coat 
influences both the colloidal stability of the core-shell formulation as well as its intracellular siRNA 
delivery potential. 
Table 1. Representative DLS data and ζ-potential of different formulations used in this study. 
Sample Hydrodynamic Diameter (nm) Ð ζ -Potential (mV) 
NGs DOPC:PG 168 ± 2 0.24 −23 ± 1 
NGs DPPC:PG 257 ± 2 0.45 −20 ± 1 
NGs DSPC:PG 5480 ± 2700 1 −16 ± 0 
Dex-HEMA NGs 195 ± 3 0.18 17 ± 0 
Dex-HEMA NGs LIP 160 ± 1 0.24 −29 ± 1 
Dex-HEMA NGs LIP SP-B 158 ± 3 0.26 −35 ± 0 
Dex-MA NGs 203 ± 1 0.26 15 ± 3 
Dex-MA NGs LIP 117 ± 1 0.26 −35 ± 0 
Dex-MA NGs LIP SP-B 114 ± 2 0.39 −40 ± 1 
DOTAP:DOPE LPX 132 ± 3 0.40 56 ± 4 
DOTAP:DOPE LPX SP-B 114 ± 2 0.38 48 ± 2 
Nanogels (NGs); Dextran hydroxyethyl methacrylate (dex-HEMA); dextran methacrylate (dex-
MA); lipid coating DOPC:PG (LIP); Surfactant Protein B (SP-B); lipoplexes (LPX); polydispersity (Ð). 
Samples were measured in HEPES buffer 20 mM pH 7.4. 
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Figure 3. Impact of lipid phase transition temperature on formation and delivery efficiency of SP-B 
containing proteolipid-coated nanogels. (a) Evaluation of eGFP silencing in H1299_eGFP cells by 
uncoated or (proteo)lipid-coated siNGs with different lipid mixtures, supplemented with 0.4 wt% SP-
B. All experiments were performed with a fixed NG concentration (30 µg/mL) and siRNA 
concentration (50 nM). The SP-B effect is strongly influenced by the type of lipid with which it is 
combined, highlighting the importance of a fluid lipid membrane in the formulation of the core-shell 
nanocomposites. (b) Chemical structures and phase transition temperatures (Tc) of the different PC 
lipids tested. Statistical analysis was performed via an unpaired t-test. Data are represented as the 
mean ± SD (n = 2) and statistical significance is indicated (**** p < 0.0001, ns = not significant).  
Natural PS contains a substantial fraction of neutral lipids, mainly cholesterol (~8 wt%), which 
modulate surfactant activity [38]. However, excessive cholesterol levels are known to interfere with 
normal surfactant function, possibly contributing to respiratory insufficiency [39,40]. As the 
manufacturing of Curosurf® involves depletion of neutral lipids, including cholesterol and 
cholesteryl esters, the data shown in Figure 2 and in earlier reports seem to indicate that the presence 
of cholesterol is not strictly required for the siRNA delivery-promoting effect of SP-B. However, state-
of-the-art lipid formulations often contain high fractions of cholesterol (up to 40 wt%) as a stabilizing 
component for in vivo application. Therefore, we sought to probe the impact of cholesterol on SP-B 
mediated siRNA delivery (Figure 4). While supplementation of the DOPC:eggPG lipid mixture with 
physiological cholesterol levels did not negatively influence siRNA delivery efficiency, gene silencing 
efficiency was slightly impaired when further increasing the cholesterol fraction to ~25 wt%. Overall, 
we conclude that cholesterol levels exceeding the endogenous PS fractions by far, partially hamper 
SP-B’s beneficial effect on siRNA delivery. 
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Figure 4. Impact of cholesterol on biological efficacy of proteolipid-coated nanogels. Evaluation of (a) 
cellular uptake and (c) gene silencing potential in H1299_eGFP cells of siRNA-loaded nanogels 
(siNGs) coated with lipid mixtures containing physiological cholesterol (CHOL) levels (2.5, 5 to 10 
wt%). Data show one representative (technical triplicate) of two independent experiments; 
formulations with different siRNA concentrations showed the same trend (data not shown). 
Evaluation of (b) cellular uptake and (d) gene silencing potential of siNGs coated with increased 
cholesterol fraction in the outer layer (~25 wt%) (n = 3). Cholesterol exceeding physiological levels 
partially hinder SP-B promoted siRNA delivery. All experiments were performed with a fixed NG 
concentration (30 µg/mL) and siRNA concentration (50 nM). LIP = DOPC:PG (85:15); LIP SP-B = 
DOPC:PG (85:15) + SP-B 0.4 wt%; LIP SP-B CHOL = DOPC:CHOL:PG (60:25:15) + SP-B 0.4 wt%. Data 
are represented as the mean ± SD and statistical significance is indicated (* p < 0.05, ** p < 0.01, *** p < 
0.005, **** p < 0.0001, ns = not significant). 
While anionic phospholipids are generally present in rather low concentrations in mammalian 
tissues, PS represents an exception with its PG content of 7–12% by mass [41]. As mentioned above, 
SP-B is a cationic amphipathic protein, of which the positive charges are believed to interact with the 
head groups of anionic phospholipid species like PG. As previously reported, this interaction could 
orchestrate the distribution of SP-B in the more disordered phases of PS membranes [42,43]. It is 
conceivable that SP-B likewise connects electrostatically with the PG fraction in the nanocomposite 
proteolipid coat, mimicking the natural interaction of SP-B with lipid bilayers. However, PG does not 
constitute the only negative phospholipid in PS, where phosphatidylinositol (PI) and 
phosphatidylserine (PhS) also play a role. Of note, PI represent the main negative phospholipid in 
lung surfactant of other species, while in humans only fetal surfactant shows higher PI content 
relative to PG, which is reversed with ageing [41]. The less abundant PhS seems to be mainly involved 
in surfactant metabolism processes, although its exact role is still unclear [41]. Here, we aimed to 
evaluate the compatibility of SP-B with other anionic lipids by replacing the PG fraction with PhS or 
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PI in the SP-B supplemented DOPC:PG proteolipid coat of the nanocomposites (Figure 5). As 
expected, all coated formulations substantially reduced the cellular uptake of the siNGs (>10-fold). 
PI containing nanocomposites reached the highest knockdown levels, which could in part be 
explained by the relatively higher intracellular siRNA dose. Most importantly, independent of the 
type of anionic lipid, the presence of SP-B in the lipid coat significantly promotes gene silencing 
efficiency, indicating that the nature of the negative phospholipid is not critical for the cellular effect 
of SP-B (Figure 5). 
 
Figure 5. Role of the anionic lipid in biological efficacy of proteolipid-coated nanogels. (a) Cellular 
uptake and (b) gene silencing evaluated on H1299_eGFP cells via flow cytometry. SiRNA-loaded 
nanogels (siNGs) were coated with a mixture of DOPC:PG, DOPC:PhS or DOPC:PI (weight ratio 
85:15). The presence of negatively charged lipids is required to allow the formation of the core-shell 
structure via electrostatic interactions. The replacement of the anionic phosphatidylglycerol (PG) with 
phosphatidylserine (PhS) or phosphatidylinositol (PI) does not abrogate SP-B’s beneficial effect on 
siRNA delivery. All experiments were performed with a fixed NG concentration (30 µg/mL) and 
siRNA concentration (50 nM). Statistical analysis was performed via an unpaired t-test. Data are 
represented as the mean ± SD (n = 3) and statistical significance is indicated (* p < 0.05, ** p < 0.01,  **** 
p < 0.0001, ns = not significant). 
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3.3. Degradability of the Nanogel Core Does Not Influence SP-B Activity 
To date, the effect of SP-B on siRNA delivery has only been demonstrated using PS-inspired 
proteolipid nanocomposites with a biodegradable hydrogel core (Figure 1). To evaluate whether the 
degradation of the core contributes to the activity of SP-B, the hydrolysable dex-HEMA NG core was 
replaced by its stable dex-MA counterpart with comparable physicochemical characteristics (Figure 
6) [28–30]. In line with earlier data from our group [31,44], dex-MA siNGs show a slightly reduced 
intrinsic siRNA delivery potential relative to dex-HEMA siNGs (due to the absence of the 
hydrolysable carbonate ester in the crosslinks), albeit similar uptake levels are achieved (data not 
shown). However, coating of the former with a SP-B proteolipid bilayer also strongly promoted 
siRNA delivery and target gene knockdown, indicating that degradability of the core material is not 
essential for SP-B’s activity (Figure 6a). 
 
Figure 6. Impact of dextran nanogel core structure on SP-B mediated siRNA delivery. (a) Gene 
silencing potential of (proteolipid-coated) siRNA-loaded NGs (siNGs) constructed with the 
hydrolysable dex-HEMA or the stable dex-MA. Both formulations were coated with a mixture of 
DOPC:PG (85:15 wt%) here abbreviated as LIP, with or without SP-B. Although the stable dex-MA 
shows a less pronounced eGFP knockdown, SP-B promotes siRNA delivery equal to the degradable 
dex-HEMA. Data are a summary of two independent experiments. Data are represented as the mean 
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± SD (n = 2) and statistical significance is indicated (** p < 0.01, *** p < 0.005, ns = not significant). (b) 
Gene silencing of (proteo)lipid-coated dex-HEMA NGs with an intact or degraded NG core. All 
experiments were performed with a fixed NG concentration (30 µg/mL) and siRNA concentration (5 
nM). Data show one representative graph of two independent experiments; formulations with 
increased SP-B fraction showed the same trend (data not shown).  
In addition, intentionally degrading the dex-HEMA NG core (4 h incubation at 37 °C) after 
proteolipid coating but prior to transfection did not seem to affect the gene knockdown efficiency 
(Figure 6b). These results indicate that an intact polymeric core material in the core-shell 
nanocomposites is likewise not essential to the delivery-promoting effect of SP-B. 
3.4. Integration of SP-B into Cationic Liposomes Does Not Enhance siRNA Delivery 
To form a stable core-shell nanocomposite, electrostatic interaction of a negatively charged lipid 
shell with the cationic NG core is required [19,24]. Here, the NG enables siRNA encapsulation in the 
nanocomposite and at the same time serves as a solid support for the deposition of the surfactant 
shell. However, as the integrity of the core material is not essential for SP-B’s effect on siRNA 
delivery, we aimed to evaluate the impact of SP-B supplementation in cationic liposomes in which 
the siRNA complexation is directly achieved by the positively-charged lipids. To date, cationic lipid 
nanoparticles (LNPs) remain the most advanced nanoformulation for siRNA delivery [45]. LNPs are 
typically composed of a cationic lipid and one or more helper lipids, in which the cationic lipid is the 
dominant component as it enables both electrostatic complexation of the oppositely charged RNA as 
well as cellular delivery by facilitating cellular uptake and endosomal escape, albeit that the latter 
step in general lacks efficiency for the majority of siRNA nanomedicines [46]. Increasing the cytosolic 
delivery potential of such formulations could reduce the dose of both carrier and cargo, thus 
mitigating the risk of off-target effects. Here, we aimed to exploit the amphiphilic properties of SP-B 
to reconstitute SP-B in the bilayer of a commercially available cationic liposomal formulation (i.e., 
DOTAP:DOPE 50:50 mol%). To obtain the lipoplexes (LPX), the formed liposomes were incubated 
with siRNA solutions to obtain a charge ratio equal to 8 [47]. Adding 1 wt% of SP-B to the lipid 
composition seemed to slightly reduce both hydrodynamic diameter as well as surface charge (Table 
1). Likewise, also the cellular internalization in the H1299 cell model was decreased when SP-B was 
present in the DOTAP:DOPE bilayer, albeit without reaching statistical significance. Most 
importantly, although higher SP-B fractions were applied here, no beneficial effect on intracellular 
siRNA delivery and resulting target gene silencing could be noted in the presence of SP-B (Figure 7). 
It is hypothesized that the high intrinsic cationic charge density of the DOTAP:DOPE liposomes 
might obscure the more subtle membrane destabilizing effects of the cationic amphiphilic SP-B 
protein. On the other hand, it cannot be excluded that electrostatic repulsion between cationic lipids 
and positively-charged SP-B molecules could result in a less optimal distribution of the protein to 
enable intracellular siRNA delivery. More detailed experiments are required to fully elucidate the 
contrasting effects of SP-B when reconstituted in DOTAP:DOPE cationic liposomes. 
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Figure 7. Evaluation of SP-B effect on DOTAP:DOPE liposomes for siRNA delivery in H1299_eGFP 
cells. (a) Cellular uptake and (b) gene silencing potential of DOTAP:DOPE LPXs (final concentrations 
siRNA are 0.5, 1 and 5 nM) with and without SP-B (1 wt%). The inclusion of SP-B in the cationic 
liposomal formulation does not result in any enhanced delivery effect. For uptake data, statistical 
analysis was performed using a one sample t-test. Data are represented as the mean ± SD (n = 2) and 
statistical significance is indicated (ns = not significant). 
4. Conclusions 
Previous studies have identified the endogenous surfactant protein B (SP-B) as siRNA delivery 
enhancer when reconstituted in lipid-coated nanogels (NGs). The mechanism of action of SP-B at the 
alveolar air-liquid interface has been investigated in detail, providing essential knowledge of the 
impact of the lipid microenvironment on SP-B’s activity and, consequently, on surfactant dynamics. 
Contrarily, the way SP-B is able to promote intracellular delivery of siRNA and how this activity 
might be influenced by the lipid environment has not yet been described in detail. Here, we evaluated 
the influence of the main constituents of SP-B proteolipid-coated NGs, namely the lipid composition 
of the proteolipid coat and the degradability of the NG core, on the activity of SP-B. While the inner 
core degradability did not seem to be essential for SP-B promoted siRNA delivery, we showed a 
crucial role of the surrounding lipid membranes. Specifically, we described the importance of 
membrane fluidity and appropriate cholesterol levels, in analogy with the physiological interactions 
between SP-B and lipids occurring at the alveolar air-liquid interface. In addition, the adjuvant effect 
of SP-B on cellular siRNA delivery was supported by different types of anionic lipid species in the 
proteolipid coat. On the other hand, a formulation of commonly used DOTAP:DOPE cationic 
liposomes with SP-B did not result in an improved gene silencing effect. Importantly, we also showed 
the SP-B promoted siRNA delivery in other pulmonary cell lines, suggesting its suitability to boost 
siRNA delivery in extrapulmonary tissues as well. Altogether, these results provide useful insights 
that will support future rational design of lipid-based SP-B nanoplatforms for siRNA delivery. 
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